

NOVO NORDISK A S
Form 6-K
April 01, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

April 1, 2016

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Status regarding Novo Nordisk's holding of its own shares (31 March 2016)

Bagsværd, Denmark, 01 April 2016 – In continuation of the company's announcements dated 29 October 2015 and 3 February 2016 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 March 2016 owned 58,672,645 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 11,734,529 or 2.3% of the total share capital.

Edgar Filing: NOVO NORDISK A S - Form 6-K

In the first quarter of 2016 a total of 10,670,964 B shares were repurchased, and 4,167,022 B shares were disposed to employees in connection with employee incentive programmes.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

Further information

Media:

Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com

Investors:

Peter Hugrefte Ankersen +45 3075 9085 phak@novonordisk.com

Daniel Bohsen +45 3079 6376 dabo@novonordisk.com

Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com

Kasper Veje +45 3079 8519 kpvj@novonordisk.com

	Telephone:	Internet:
Novo Nordisk A/S	+45 4444 8888	www.novonordisk.com
Investor Relations	Telefax:	CVR no:
Novo Allé 2880 Bagsværd Denmark	+45 4444 6626	24 25 67 90
	Company announcement No 26 / 2016	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: April 1, 2016

Lars Rebien Sørensen

Chief Executive Officer